Donna L. Topping's research while affiliated with Duke University and other places

Publications (5)

Article
Background: Stromal tumor-infiltrating lymphocytes (TILs) might predict pathologic complete response (pCR) in patients with HER2-positive (HER2+) breast cancer treated with trastuzumab (H). Docetaxel (T), carboplatin (C), H, and pertuzumab (P) have immune-modulating effects. Pre- and post-treatment immune biomarkers in cancers treated with neoadju...
Article
Full-text available
Background Cyclin-dependent kinase (CDK) 4/6 inhibitor-based therapies have shown great promise in improving clinical outcomes for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer. Objectives 1. Discuss the mode of action of the three CDK4/6 inhibitors in late clinical...
Article
Background: Baseline TIL density and T-cell clonality predict pathological complete response (pCR) to neoadjuvant (NA) trastuzumab (TRAS). Preclinical data suggests that a major mechanism of TRAS is enhancement of antibody-dependent cytoxicity (ADCC) and T-cell mediated tumor kill and that the combination of TRAS with pertuzumab (PERT) may enhance...
Article
1076 Background: The FN rate for the approved regimen of TC is 5% in pivotal studies. Other small retrospective reports have reported FN rates as high as 20-35%. We report the incidence of FN from a large retrospective series of breast cancer patients receiving TC with or without pegfilgrastim (PF) for adjuvant therapy. Methods: We reviewed records...

Citations

... Significant reductions in FN incidence for pegfilgrastim primary prophylaxis versus no pegfilgrastim primary prophylaxis were also seen in observational studies of patients with breast cancer (4 % vs 30 %) and in patients with various tumour types (odds ratio [95 % confidence interval (CI)]= 0.49 [0.34-0.68]) [48,41]. ...
... Nevertheless, high Treg TIL quantities without CD8+ T cells were not associated with better survival in ER-positive breast cancer patients [63]. Based on the studies to date, further research is needed to clarify the role of Treg cells in tumoral immune response and their interaction with other cell populations present in the tumor [64]. Thus, future studies on their prognostic role in patient samples are necessary to finally determine the clinical importance of Treg cell assessment. ...
... Preliminary data from the phase I clinical trial of LY3484356 demonstrated encouraging results at lower doses (400 mg, orally once daily), however, higher doses were associated with progressive disease (Table 1) [93]. Additionally, a significant number of patients experienced diarrhea (22%) and nausea (35%) which will likely limit the use of LY3484356 in the adjuvant setting in combination with CDK4/6 inhibitors, which demonstrate significant gastrointestinal side effects as monotherapies [93,94]. Preliminary data from the Phase I/II clinical trial of amcenestrant showed exceptional efficacy in patients with advanced ER+ breast cancer, although only 56.4% of patients had received prior endocrine therapy and only 5.4% had received prior CDK4/6 inhibitors (Table 1) [95]. ...